CS 231295
Alternative Names: CS-231295Latest Information Update: 21 Oct 2024
At a glance
- Originator Chipscreen Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Brain metastases; Glioblastoma; Pancreatic cancer; Small cell lung cancer; Triple negative breast cancer
Most Recent Events
- 17 Oct 2024 National Medical Products Administration of China accepts IND application for CS 231295 for Solid tumoura in China
- 16 Oct 2024 Chipscreen Biosciences files an IND application with the National Medical Products Administration in China for Solid tumours prior to October 2024
- 03 Jan 2024 Preclinical trials in Brain metastases in China (PO), prior to January 2024 (Chipscreen Biosciences pipeline, January 2024)